BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36574856)

  • 21. Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
    van Eenige R; Ying Z; Tramper N; Wiebing V; Siraj Z; de Boer JF; Lambooij JM; Guigas B; Qu H; Coskun T; Boon MR; Rensen PCN; Kooijman S
    Atherosclerosis; 2023 May; 372():19-31. PubMed ID: 37015151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis.
    Christoffersen C; Pedersen TX; Gordts PL; Roebroek AJ; Dahlbäck B; Nielsen LB
    Circ Res; 2010 May; 106(10):1624-34. PubMed ID: 20360257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice.
    Kawashiri M; Zhang Y; Usher D; Reilly M; Puré E; Rader DJ
    J Lipid Res; 2001 Jun; 42(6):943-50. PubMed ID: 11369802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor.
    Knouff C; Briand O; Lestavel S; Clavey V; Altenburg M; Maeda N
    Biochim Biophys Acta; 2004 Aug; 1684(1-3):8-17. PubMed ID: 15450205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice.
    Wang Y; Tang W; Yang P; Shin H; Li Q
    Biochem Biophys Res Commun; 2018 May; 499(3):626-633. PubMed ID: 29601818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adipocyte enhancer-binding protein 1 (AEBP1) (a novel macrophage proinflammatory mediator) overexpression promotes and ablation attenuates atherosclerosis in ApoE (-/-) and LDLR (-/-) mice.
    Bogachev O; Majdalawieh A; Pan X; Zhang L; Ro HS
    Mol Med; 2011; 17(9-10):1056-64. PubMed ID: 21687917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway.
    Mortimer BC; Beveridge DJ; Martins IJ; Redgrave TG
    J Biol Chem; 1995 Dec; 270(48):28767-76. PubMed ID: 7499399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.
    Medh JD; Fry GL; Bowen SL; Ruben S; Wong H; Chappell DA
    J Lipid Res; 2000 Nov; 41(11):1858-71. PubMed ID: 11060356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both.
    Ishibashi S; Perrey S; Chen Z; Osuga Ji; Shimada M; Ohashi K; Harada K; Yazaki Y; Yamada N
    J Biol Chem; 1996 Sep; 271(37):22422-7. PubMed ID: 8798405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
    Post SM; de Roos B; Vermeulen M; Afman L; Jong MC; Dahlmans VE; Havekes LM; Stellaard F; Katan MB; Princen HM
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atherogenic and pulmonary responses of ApoE- and LDL receptor-deficient mice to sidestream cigarette smoke.
    Han SG; Howatt DA; Daugherty A; Gairola CG
    Toxicology; 2012 Sep; 299(2-3):133-8. PubMed ID: 22659316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
    Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
    Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of adipocyte lipoprotein lipase on de novo lipogenesis and white adipose tissue browning.
    Bartelt A; Weigelt C; Cherradi ML; Niemeier A; Tödter K; Heeren J; Scheja L
    Biochim Biophys Acta; 2013 May; 1831(5):934-42. PubMed ID: 23228690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):14-28. PubMed ID: 10685027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ; van Dijk KW; van't Hof HB; van Gorp PJ; van der Zee A; van der Boom H; Breuer ML; Hofker MH; Havekes LM
    J Biol Chem; 1996 Nov; 271(48):30595-602. PubMed ID: 8940032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol.
    Espirito Santo SM; Pires NM; Boesten LS; Gerritsen G; Bovenschen N; van Dijk KW; Jukema JW; Princen HM; Bensadoun A; Li WP; Herz J; Havekes LM; van Vlijmen BJ
    Blood; 2004 May; 103(10):3777-82. PubMed ID: 14739216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.